Michael P. Tarnok is Director at KERYX BIOPHARMACEUTICALS INC (KERX). They have made 5 open-market trades across 1 company since 2007, most recently 2025-06-20.
CIK 0001413525
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $199K since 2007, never a sale. Across 5 scored buys the stock is down 1.8% at ninety days, and 2.1 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 0% | 0% |
| Avg Move | -32.6% | -1.8% | -1.8% |
| Alpha | -26.8% | -2.1% | -2.1% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| KERX | BUY | 2015-05-06 | 2015-05-06 | $9.73 | $97K | -32.6% | -1.8% | -1.8% |
| KERX | BUY | 2012-04-05 | 2012-04-09 | $1.55 | $27K | -32.6% | -1.8% | -1.8% |
| KERX | BUY | 2011-08-10 | 2011-08-11 | $3.10 | $47K | -32.6% | -1.8% | -1.8% |
| KERX | BUY | 2009-05-26 | 2009-05-27 | $0.46 | $18K | -32.6% | -1.8% | -1.8% |
| KERX | BUY | 2007-11-19 | 2007-11-20 | $8.71 | $10K | -32.6% | -1.8% | -1.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.